Free Trial
→ Elon’s 2025 Silver Crisis (What It Means for You) (From GoldenCrest Metals) (Ad) Buy EWTX Stock  Free EWTX Stock Alerts

Edgewise Therapeutics (EWTX) Financials

Edgewise Therapeutics logo
$14.33 0.00 (0.00%)
As of 01:06 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Edgewise Therapeutics

Annual Income Statements for Edgewise Therapeutics

This table shows Edgewise Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Net Income / (Loss) Attributable to Common Shareholders		 -134 -100 -68 -43 -17
Consolidated Net Income / (Loss)		 -134 -100 -68 -43 -17
Net Income / (Loss) Continuing Operations		 -134 -100 -68 -43 -17
Total Pre-Tax Income 		-134 -100 -68 -43 -17
Total Operating Income		 -159 -114 -72 -43 -17
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 159 114 72 43 17
Selling, General & Admin Expense		 32 23 18 11 2.21
Research & Development Expense		 127 91 54 32 15
Total Other Income / (Expense), net		 25 14 4.02 0.40 0.07
Interest & Investment Income		 25 14 4.02 0.40 0.07
Weighted Average Basic Shares Outstanding		 92.41M 63.72M 53.59M 37.53M 739.00K
Weighted Average Diluted Shares Outstanding		 92.41M 63.72M 53.59M 37.53M 739.00K
Weighted Average Basic & Diluted Shares Outstanding		 95.21M 93.11M 63.26M 49.51M -

Quarterly Income Statements for Edgewise Therapeutics

This table shows Edgewise Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -41 -42 -32 -32 -29 -30 -26 -22 -23 -19 -17
Consolidated Net Income / (Loss)		 -41 -40 -34 -31 -29 -30 -26 -21 -23 -19 -17
Net Income / (Loss) Continuing Operations		 -41 -40 -34 -31 -29 -30 -26 -21 -23 -19 -17
Total Pre-Tax Income 		-41 -40 -34 -31 -29 -30 -26 -21 -23 -19 -17
Total Operating Income		 -46 -46 -40 -38 -35 -34 -29 -25 -26 -22 -18
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 46 46 40 38 35 34 29 25 26 22 18
Selling, General & Admin Expense		 9.20 9.17 8.21 7.43 7.06 6.18 5.67 5.78 5.83 5.47 4.37
Research & Development Expense		 37 36 32 31 28 28 24 20 20 17 14
Total Other Income / (Expense), net		 5.16 5.88 6.30 6.61 6.23 3.72 3.74 3.87 2.87 2.66 0.76
Interest & Investment Income		 5.16 5.88 6.30 6.61 6.23 3.72 3.74 3.87 2.87 2.66 0.76
Weighted Average Basic Shares Outstanding		 95.13M 92.41M 93.81M 93.52M 87.57M 63.72M 63.46M 63.38M 63.27M 53.59M 51.84M
Weighted Average Diluted Shares Outstanding		 95.13M 92.41M 93.81M 93.52M 87.57M 63.72M 63.46M 63.38M 63.27M 53.59M 51.84M
Weighted Average Basic & Diluted Shares Outstanding		 105.20M 95.21M 94.69M 93.77M 93.40M 93.11M 63.46M 63.46M 63.28M 63.26M -

Annual Cash Flow Statements for Edgewise Therapeutics

This table details how cash moves in and out of Edgewise Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Net Change in Cash & Equivalents		 -44 64 6.43 -89 81
Net Cash From Operating Activities		 -109 -92 -53 -34 -15
Net Cash From Continuing Operating Activities		 -109 -92 -53 -34 -15
Net Income / (Loss) Continuing Operations		 -134 -100 -68 -43 -17
Consolidated Net Income / (Loss)		 -134 -100 -68 -43 -17
Depreciation Expense		 2.07 1.55 0.37 0.27 0.19
Amortization Expense		 -12 -9.34 -0.37 0.00 -
Non-Cash Adjustments To Reconcile Net Income		 25 18 11 4.40 0.35
Changes in Operating Assets and Liabilities, net		 10 -1.56 4.09 4.63 1.95
Net Cash From Investing Activities		 -185 103 -71 -242 -24
Net Cash From Continuing Investing Activities		 -185 103 -71 -242 -24
Purchase of Property, Plant & Equipment		 -1.31 -5.75 -5.55 -0.67 -0.20
Purchase of Investments		 -477 -256 -292 -288 -24
Sale and/or Maturity of Investments		 294 364 227 47 0.00
Net Cash From Financing Activities		 249 53 130 186 120
Net Cash From Continuing Financing Activities		 249 53 130 186 120
Repayment of Debt		 -0.26 -0.17 -0.25 0.00 -
Issuance of Common Equity		 240 53 129 186 0.00
Other Financing Activities, net		 9.48 0.12 0.41 0.11 0.20

Quarterly Cash Flow Statements for Edgewise Therapeutics

This table details how cash moves in and out of Edgewise Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 8.26 -3.14 1.32 13 -56 53 1.15 -16 26 -88 91
Net Cash From Operating Activities		 -38 -27 -27 -26 -29 -27 -22 -20 -23 -12 -12
Net Cash From Continuing Operating Activities		 -38 -27 -27 -26 -29 -27 -22 -20 -23 -12 -12
Net Income / (Loss) Continuing Operations		 -41 -40 -34 -31 -29 -30 -26 -21 -23 -19 -17
Consolidated Net Income / (Loss)		 -41 -40 -34 -31 -29 -30 -26 -21 -23 -19 -17
Depreciation Expense		 0.51 0.58 0.54 0.48 0.47 0.48 0.45 0.42 0.20 0.09 0.10
Amortization Expense		 -1.88 -2.55 -3.18 -3.50 -3.10 -2.12 -2.33 -2.86 -2.03 -1.75 0.19
Non-Cash Adjustments To Reconcile Net Income		 8.88 8.25 6.37 5.39 4.71 5.14 4.57 4.01 3.84 3.74 3.17
Changes in Operating Assets and Liabilities, net		 -4.58 6.43 3.03 3.03 -2.16 -0.19 0.96 -0.34 -1.99 5.49 2.07
Net Cash From Investing Activities		 44 21 25 37 -268 27 23 3.44 49 -76 -26
Net Cash From Continuing Investing Activities		 44 21 25 37 -268 27 23 3.44 49 -76 -26
Purchase of Property, Plant & Equipment		 0.00 -1.11 0.31 -0.22 -0.30 -0.16 -0.46 -0.76 -4.37 -3.29 -1.33
Purchase of Investments		 -122 -63 -45 -41 -328 -40 -85 -114 -17 -147 -68
Sale and/or Maturity of Investments		 166 84 71 79 60 67 109 119 70 74 43
Other Investing Activities, net		 -0.04 - - - - - - - - - -
Net Cash From Financing Activities		 2.22 2.90 3.33 1.95 241 53 -0.21 0.37 0.02 -0.30 130
Net Cash From Continuing Financing Activities		 2.22 2.90 3.33 1.95 241 53 -0.21 0.37 0.02 -0.30 130
Repayment of Debt		 -0.04 - -0.21 - - 0.05 -0.21 - - 0.09 -0.08
Issuance of Common Equity		 0.00 0.47 - 0.42 239 53 - 0.34 0.00 -0.41 130
Other Financing Activities, net		 2.26 2.43 3.55 1.58 1.93 0.06 0.00 0.03 0.02 0.03 0.05

Annual Balance Sheets for Edgewise Therapeutics

This table presents Edgewise Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Total Assets		 487 340 367 285 131
Total Current Assets		 475 327 357 284 130
Cash & Equivalents		 42 86 22 16 105
Short-Term Investments		 429 232 330 265 24
Prepaid Expenses		 5.31 8.60 5.05 2.98 0.55
Plant, Property, & Equipment, net		 9.50 10 8.53 0.91 0.52
Total Noncurrent Assets		 1.83 2.60 1.57 0.55 0.98
Other Noncurrent Operating Assets		 1.83 2.60 1.57 0.00 0.98
Total Liabilities & Shareholders' Equity		 487 340 367 285 131
Total Liabilities		 28 21 20 11 4.34
Total Current Liabilities		 24 17 17 11 4.34
Accounts Payable		 5.58 4.03 6.11 3.84 1.58
Accrued Expenses		 7.23 6.07 5.84 3.88 1.59
Current Employee Benefit Liabilities		 10 5.70 4.03 2.80 1.18
Other Current Liabilities		 1.00 0.98 0.61 0.00 -
Total Noncurrent Liabilities		 3.74 4.43 3.80 0.33 0.00
Other Noncurrent Operating Liabilities		 3.74 4.43 3.80 0.33 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 459 319 347 274 -33
Total Preferred & Common Equity		 459 319 347 274 -33
Preferred Stock		 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 459 319 347 274 -33
Common Stock		 837 563 493 352 0.73
Retained Earnings		 -379 -245 -145 -77 -34
Accumulated Other Comprehensive Income / (Loss)		 0.42 0.10 -1.36 -0.51 0.00

Quarterly Balance Sheets for Edgewise Therapeutics

This table presents Edgewise Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023
Total Assets		 454 511 532 554 311 331 346
Total Current Assets		 443 499 519 541 298 317 333
Cash & Equivalents		 50 45 43 30 33 32 48
Short-Term Investments		 386 448 468 502 257 278 280
Prepaid Expenses		 6.79 6.90 7.69 8.67 8.22 7.07 5.41
Plant, Property, & Equipment, net		 8.99 9.97 9.90 10 11 11 10
Total Noncurrent Assets		 2.22 1.88 2.31 2.20 2.76 2.77 2.64
Other Noncurrent Operating Assets		 2.22 1.88 2.31 2.20 2.76 2.77 2.64
Total Liabilities & Shareholders' Equity		 454 511 532 554 311 331 346
Total Liabilities		 25 22 21 19 21 19 18
Total Current Liabilities		 21 19 17 15 16 14 13
Accounts Payable		 8.79 5.65 6.80 4.72 5.32 3.78 3.88
Accrued Expenses		 7.35 6.13 5.14 5.97 5.68 6.62 5.97
Current Employee Benefit Liabilities		 3.97 6.19 4.24 2.92 4.41 3.13 2.07
Other Current Liabilities		 1.00 0.99 0.99 0.98 0.93 0.87 0.80
Total Noncurrent Liabilities		 3.56 3.45 4.00 4.27 4.60 4.77 4.85
Other Noncurrent Operating Liabilities		 3.56 3.45 4.00 4.27 4.60 4.77 4.85
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 430 489 510 535 290 311 329
Total Preferred & Common Equity		 430 489 510 535 290 311 329
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 430 489 510 535 290 311 329
Common Stock		 849 827 816 809 505 501 497
Retained Earnings		 -419 -339 -305 -273 -215 -189 -167
Accumulated Other Comprehensive Income / (Loss)		 0.40 1.05 -1.05 -0.86 -0.42 -0.55 -0.25

Annual Metrics And Ratios for Edgewise Therapeutics

This table displays calculated financial ratios and metrics derived from Edgewise Therapeutics' official financial filings.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Growth Metrics		 - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -38.43% -70.44% -66.88% -152.50% 0.00%
EBIT Growth		 -38.89% -59.59% -65.82% -151.37% 0.00%
NOPAT Growth		 -38.89% -59.59% -65.82% -151.37% 0.00%
Net Income Growth		 -33.60% -48.08% -57.99% -150.03% 0.00%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 -18.58% -74.69% -57.09% -128.97% 0.00%
Free Cash Flow Firm Growth		 -16.42% -65.21% -102.70% 0.00% 0.00%
Invested Capital Growth		 -2,606.64% 108.35% 24.78% -202.35% 0.00%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -7.65% -10.65% 0.00% -30.72% 0.00%
EBIT Q/Q Growth		 -7.94% -11.49% 0.00% -30.58% 0.00%
NOPAT Q/Q Growth		 -7.94% -11.49% 0.00% -30.58% 0.00%
Net Income Q/Q Growth		 -7.66% -12.00% 0.00% -17.43% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -0.12% -19.45% 0.00% -16.64% 0.00%
Free Cash Flow Firm Q/Q Growth		 -1.19% -18.18% -920.33% 0.00% 0.00%
Invested Capital Q/Q Growth		 -199.37% -40.14% 0.00% -36.76% 0.00%
Profitability Metrics		 - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 84.25% 87.59% 94.39% 99.07% 99.60%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -34.40% -30.10% -21.78% -21.34% -13.50%
Cash Return on Invested Capital (CROIC)		 0.00% -19,615.08% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -34.40% -30.10% -21.78% -12.82% 3.56%
Return on Equity Simple (ROE_SIMPLE)		 -29.14% -31.42% -19.51% -15.60% 51.24%
Net Operating Profit after Tax (NOPAT)		 -111 -80 -50 -30 -12
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -5.74% -6.00% -5.52% -6.12% -3.94%
Return On Investment Capital (ROIC_SIMPLE)		 -24.21% -25.11% - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -159 -114 -72 -43 -17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -169 -122 -72 -43 -17
Valuation Ratios		 - - - - -
Price to Book Value (P/BV)		 5.51 2.18 1.28 2.75 0.00
Price to Tangible Book Value (P/TBV)		 5.51 2.18 1.28 2.75 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 860.13 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.01 -1.01 -1.02 -1.02 -1.02
Leverage Ratio		 1.06 1.06 1.05 1.04 1.03
Compound Leverage Factor		 0.90 0.93 0.99 1.03 1.03
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 126.36%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% -26.36%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 53.91 18.62 13.02 41.93 24.67
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 39.94% 126.36%
Liquidity Ratios		 - - - - -
Current Ratio		 19.93 19.50 21.53 26.97 29.86
Quick Ratio		 19.71 18.98 21.22 26.69 29.73
Cash Flow Metrics		 - - - - -
Free Cash Flow to Firm (FCFF)		 -100 -86 -52 -26 0.00
Operating Cash Flow to CapEx		 -8,310.06% -1,600.49% -949.06% -5,016.02% -7,208.87%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - -
Invested Capital		 -11 0.44 -5.23 -6.95 -2.30
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -11 5.67 1.72 -4.65 0.00
Enterprise Value (EV)		 2,058 376 93 472 207
Market Capitalization		 2,528 694 445 753 176
Book Value per Share		 $4.85 $5.02 $6.47 $5.57 ($45.22)
Tangible Book Value per Share		 $4.85 $5.02 $6.47 $5.57 ($45.22)
Total Capital		 459 319 347 274 127
Total Debt		 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00
Net Debt		 -470 -318 -352 -281 -129
Capital Expenditures (CapEx)		 1.31 5.75 5.55 0.67 0.20
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -19 -8.17 -12 -7.54 -3.79
Debt-free Net Working Capital (DFNWC)		 452 310 340 273 125
Net Working Capital (NWC)		 452 310 340 273 125
Net Nonoperating Expense (NNE)		 23 20 17 13 5.09
Net Nonoperating Obligations (NNO)		 -470 -318 -352 -281 -129
Total Depreciation and Amortization (D&A)		 -10 -7.79 -0.01 0.27 0.19
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 92.41M 63.72M 53.59M 37.53M 0.00
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 92.41M 63.72M 53.59M 37.53M 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 95.21M 93.11M 63.26M 49.51M 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -111 -80 -50 -30 -12
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% -0.29% 0.00%

Quarterly Metrics And Ratios for Edgewise Therapeutics

This table displays calculated financial ratios and metrics derived from Edgewise Therapeutics' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -26.62% -33.84% -37.47% -48.08% -35.73% -49.53% -74.35% -74.43% -96.29% 0.00% -38.10%
EBIT Growth		 -32.24% -34.49% -37.28% -50.39% -35.20% -53.37% -61.27% -53.65% -73.37% 0.00% -39.66%
NOPAT Growth		 -32.24% -34.49% -37.28% -50.39% -35.20% -53.37% -61.27% -53.65% -73.37% 0.00% -39.66%
Net Income Growth		 -43.03% -31.58% -32.73% -46.71% -24.90% -55.26% -46.95% -33.62% -55.78% 0.00% 0.00%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 -32.41% -0.47% -24.10% -28.99% -25.29% -126.32% -84.39% -24.56% -81.56% 0.00% -44.80%
Free Cash Flow Firm Growth		 8.98% 30.25% -12.03% -12.05% -5.19% -70.98% -19.46% -79.02% -190.73% -469.11% -339.22%
Invested Capital Growth		 -405.59% -2,606.64% -601.23% -183.63% 145.72% 108.35% 0.00% 174.85% 116.21% 24.78% 100.00%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.39% -10.32% -4.73% -10.03% -5.29% -13.31% -12.81% -0.85% -15.99% -32.12% -12.86%
EBIT Q/Q Growth		 -0.92% -12.63% -6.10% -9.65% -2.63% -14.97% -16.23% 1.42% -16.42% -20.90% -10.74%
NOPAT Q/Q Growth		 -0.92% -12.63% -6.10% -9.65% -2.63% -14.97% -16.23% 1.42% -16.42% -20.90% -10.74%
Net Income Q/Q Growth		 -2.86% -16.21% -8.36% -10.42% 5.37% -17.23% -19.77% 5.99% -17.63% -10.96% -8.91%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -40.47% 1.52% -4.89% 8.74% -6.59% -21.63% -9.01% 11.36% -92.54% 0.90% 26.36%
Free Cash Flow Firm Q/Q Growth		 -13.83% 14.33% -0.18% 6.83% 12.77% -37.59% -0.20% 12.54% -41.79% 3.86% -50.15%
Invested Capital Q/Q Growth		 39.13% -199.37% -186.53% -158.52% 399.31% -40.14% -52.19% 71.96% 116.98% 0.00% 100.00%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 88.77% 87.09% 84.41% 82.65% 82.08% 89.02% 87.30% 84.73% 88.85% 87.93% 95.82%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -30.29% -34.40% -31.90% -28.20% -24.51% -30.10% -61.59% -29.12% -25.74% -21.78% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% -5,711.93% -19,615.08% -19,871.73% -4,422.78% -7,223.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -30.29% -34.40% -31.90% -28.20% -24.51% -30.10% -61.59% -29.12% -25.74% -21.78% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -34.00% 0.00% -25.42% -22.70% -19.79% 0.00% -30.79% -26.08% -23.06% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -32 -32 -28 -27 -24 -24 -21 -18 -18 -15 -13
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.78% -1.97% -1.49% -1.17% -0.98% -1.92% -3.52% -1.34% -1.63% -1.25% -3.25%
Return On Investment Capital (ROIC_SIMPLE)		 -7.49% -6.94% - - - -7.43% - - - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -46 -46 -40 -38 -35 -34 -29 -25 -26 -22 -18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -47 -48 -43 -41 -37 -36 -31 -28 -28 -24 -18
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.87 5.51 5.12 3.30 2.16 2.18 1.25 1.57 1.28 1.28 0.00
Price to Tangible Book Value (P/TBV)		 4.87 5.51 5.12 3.30 2.16 2.18 1.25 1.57 1.28 1.28 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 286.33 860.13 101.27 118.20 105.87 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.00 -1.01 -1.00 -1.00 -1.00 -1.01 -1.00 -1.00 -1.01 -1.02 -1.02
Leverage Ratio		 1.05 1.06 1.06 1.05 1.04 1.06 1.07 1.05 1.05 1.05 1.03
Compound Leverage Factor		 0.93 0.93 0.89 0.87 0.86 0.95 0.94 0.89 0.93 0.92 0.99
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 50.43 54.67 66.96 47.76 37.06 19.40 10.23 15.39 14.61 13.47 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 20.99 19.93 26.35 30.24 37.08 19.50 18.23 22.01 26.22 21.53 0.00
Quick Ratio		 20.67 19.71 25.98 29.79 36.49 18.98 17.73 21.52 25.79 21.22 0.00
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -23 -20 -24 -24 -26 -29 -21 -21 -24 -17 -18
Operating Cash Flow to CapEx		 0.00% -2,432.94% 0.00% -11,809.50% -9,628.96% -16,664.60% -4,826.70% -2,665.88% -522.57% -360.01% -899.47%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -6.67 -11 -3.66 -1.28 2.18 0.44 0.73 1.53 0.89 -5.23 0.00
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -8.85 -11 -4.39 -2.80 1.29 5.67 0.73 3.57 6.37 1.72 5.09
Enterprise Value (EV)		 1,658 2,058 2,010 1,170 625 376 74 180 94 93 490
Market Capitalization		 2,095 2,528 2,503 1,682 1,158 694 364 490 422 445 490
Book Value per Share		 $4.51 $4.85 $5.21 $5.47 $6.11 $5.02 $4.58 $4.92 $5.20 $6.47 $0.00
Tangible Book Value per Share		 $4.51 $4.85 $5.21 $5.47 $6.11 $5.02 $4.58 $4.92 $5.20 $6.47 $0.00
Total Capital		 430 459 489 510 535 319 290 311 329 347 0.00
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -436 -470 -493 -512 -533 -318 -290 -310 -328 -352 0.00
Capital Expenditures (CapEx)		 0.00 1.11 -0.31 0.22 0.30 0.16 0.46 0.76 4.37 3.29 1.33
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -14 -19 -12 -9.49 -5.93 -8.17 -8.11 -7.33 -7.30 -12 0.00
Debt-free Net Working Capital (DFNWC)		 422 452 480 502 527 310 282 303 321 340 0.00
Net Working Capital (NWC)		 422 452 480 502 527 310 282 303 321 340 0.00
Net Nonoperating Expense (NNE)		 8.63 7.78 5.83 4.82 4.20 6.44 5.10 3.73 4.85 3.96 4.71
Net Nonoperating Obligations (NNO)		 -436 -470 -493 -512 -533 -318 -290 -310 -328 -352 0.00
Total Depreciation and Amortization (D&A)		 -1.37 -1.97 -2.64 -3.02 -2.63 -1.64 -1.88 -2.43 -1.83 -1.66 0.29
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 95.13M 92.41M 93.81M 93.52M 87.57M 63.72M 63.46M 63.38M 63.27M 53.59M 0.00
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 95.13M 92.41M 93.81M 93.52M 87.57M 63.72M 63.46M 63.38M 63.27M 53.59M 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 105.20M 95.21M 94.69M 93.77M 93.40M 93.11M 63.46M 63.46M 63.28M 63.26M 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -32 -32 -28 -27 -24 -24 -21 -18 -18 -15 -13
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Edgewise Therapeutics' Financials

When does Edgewise Therapeutics's financial year end?

According to the most recent income statement we have on file, Edgewise Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Edgewise Therapeutics' net income changed over the last 4 years?

Edgewise Therapeutics' net income appears to be on an upward trend, with a most recent value of -$133.81 million in 2024, rising from -$17.12 million in 2020. The previous period was -$100.16 million in 2023. See where experts think Edgewise Therapeutics is headed by visiting Edgewise Therapeutics' forecast page.

What is Edgewise Therapeutics's operating income?
Edgewise Therapeutics's total operating income in 2024 was -$158.83 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $158.83 million
How has Edgewise Therapeutics revenue changed over the last 4 years?

Over the last 4 years, Edgewise Therapeutics' total revenue changed from $0.00 in 2020 to $0.00 in 2024, a change of 0.0%.

How much debt does Edgewise Therapeutics have?

Edgewise Therapeutics' total liabilities were at $27.60 million at the end of 2024, a 30.2% increase from 2023, and a 535.7% increase since 2020.

How much cash does Edgewise Therapeutics have?

In the past 4 years, Edgewise Therapeutics' cash and equivalents has ranged from $15.57 million in 2021 to $104.92 million in 2020, and is currently $41.67 million as of their latest financial filing in 2024.

How has Edgewise Therapeutics' book value per share changed over the last 4 years?

Over the last 4 years, Edgewise Therapeutics' book value per share changed from -45.22 in 2020 to 4.85 in 2024, a change of -110.7%.


Related Companies

This page (NASDAQ:EWTX) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...
Premier Gold Co | Sponsored
F1 Engineering Powers This Electric Marine Motor
The future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...
The Tomorrow Investor | Sponsored
Trump Predicts Dollar Downfall
READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...
Augusta Precious Metals | Sponsored
Elon’s 2025 Silver Crisis (What It Means for You)
Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...
GoldenCrest Metals | Sponsored
Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsored
Big Oil’s big pivot
The Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...
Stansberry Research | Sponsored
AI Meltdown Imminent: Dump These Stocks Now!
If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...
Paradigm Press | Sponsored
Dollar Collapse Warning: Protect Your Wealth NOW
Global central banks are stockpiling gold. Billionaires are hedging with precious metals. And thousands of Ame...
Lear Capital | Sponsored